6533b82bfe1ef96bd128d794
RESEARCH PRODUCT
Dacarbazine mediate antimelanoma effects via NK cells.
Grégoire MignotAlice HervieuFrançois Ghiringhellisubject
[SDV.IMM] Life Sciences [q-bio]/ImmunologyDacarbazineImmunologyNkg2d ligandsTumor cellschemical and pharmacologic phenomenadacarbazineNK cellsMetastatic tumorNKG2DmedicinemelanomaImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyB16Author's Viewbusiness.industryMelanomamedicine.diseaseNKG2D3. Good healthOncologyImmunologyCancer research[SDV.IMM]Life Sciences [q-bio]/ImmunologybusinessCD8medicine.drugdescription
International audience; Melanoma is a highly chemoresistant and metastatic tumor that, in the absence of BRAF mutations, is generally treated with the alkylating agent dacarbazine (DTIC). We discovered that DTIC upregulates the expression of NKG2D ligands on tumor cells, leading to the activation of natural killer (NK) and CD8(+) T cells. These observations underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-04-01 |